

# Veterinary Microbiology

## Impact of animal saliva on the performance of rapid antigen tests for detection of SARS-CoV-2 (wildtype and variants B.1.1.7 and B.1.351)

--Manuscript Draft--

<b>Manuscript Number:</b>	VETMIC-D-21-00475R1
<b>Article Type:</b>	Research Paper
<b>Section/Category:</b>	Viruses
<b>Keywords:</b>	SARS-COV-2; Real-time RT-PCR; Rapid Antigen Assays, Saliva, Variants of concern (VOC)
<b>Corresponding Author:</b>	Markus Keller Friedrich-Loeffler-Institut Greifswald - Insel Riems, Germany
<b>First Author:</b>	Ibrahim T. Hagag
<b>Order of Authors:</b>	Ibrahim T. Hagag Saskia Weber Balal Sadeghi Martin H. Groschup Markus Keller
<b>Abstract:</b>	SARS-CoV-2 can infect a several animal species and SARS-CoV-2 variants of concern (VOC) may even show (as in humans) enhanced inter- and intra-species transmission rates. We correlated sensitivity data of SARS-CoV-2 rapid antigen tests (RATs) to real-time RT-PCR and checked their suitability for testing animals by assessing saliva and VOC effects. Viral loads up to 2 logs under the hypothetical SARS-CoV-2 infectivity threshold were detected by most analyzed RATs. However, while saliva from various animal species showed generally no adverse effects on the RATs' analytical sensitivities, the detection of VOCs B.1.1.7 and B.1.351 was in some RATs inferior to non-VOC viruses.
<b>Suggested Reviewers:</b>	Wim H.M. van der Poel wim.vanderpoel@wur.nl Barbara Holzer barbara.holzer@ages.at Asisa Volz asisa.volz@tiho-hannover.de Sharon Brookes sharon.brookes@apha.gov.uk
<b>Opposed Reviewers:</b>	
<b>Response to Reviewers:</b>	

# Impact of animal saliva on the performance of rapid antigen tests for detection of SARS-CoV-2 (wildtype and variants B.1.1.7 and B.1.351)

Ibrahim T. Hagag<sup>1</sup>, Saskia Weber<sup>1</sup>, Balal Sadeghi<sup>1</sup>, Martin H. Groschup<sup>1</sup>, and Markus Keller<sup>1,\*</sup>

<sup>1</sup> Institute of Novel and Emerging Infectious Diseases, Friedrich-Loeffler-Institut, 17493 Greifswald - Insel Riems, Germany.

## \*Corresponding Author:

Dr. Markus Keller, Institute of Novel and Emerging Infectious Diseases, Friedrich-Loeffler-Institut, Südufer 10, 17493 Greifswald - Insel Riems, Telefon: +49 38351 7-1190, Fax: +49 38351 7-1192, E-Mail: [Markus.Keller@fli.de](mailto:Markus.Keller@fli.de)

## Abstract

SARS-CoV-2 infects several animal species and SARS-CoV-2 variants of concern (VOCs) may even show (as in humans) enhanced inter- and intra-species transmission rates. We correlated sensitivity data of SARS-CoV-2 rapid antigen tests (RATs) to viral RNA genome equivalents assessed by real-time reverse transcriptase-polymerase chain reaction (RT-PCR). Further, we checked their suitability for testing animals by assessing saliva and VOC effects. Viral loads up to 2 logs (RNA copy number) under the hypothetical SARS-CoV-2 infectivity threshold were detected by most analyzed RATs. However, while saliva from various animal species showed generally no adverse effects on the RATs' analytical sensitivities, the detection of VOCs B.1.1.7 and B.1.351 was in some RATs inferior to non-VOC viruses.

**Keywords:** SARS-CoV-2; Real-time RT-PCR; Rapid Antigen Assays, Saliva, Variants of Concern (VOCs).

## Introduction

Seven different coronaviruses are currently known to infect humans and all of them originate from animals (Su et al., 2016). In late 2019 a betacoronavirus of unknown origin, designated SARS-CoV-2 was identified and caused a worldwide pandemic. Apart from humans, SARS-CoV-2 can infect farm animals, hamsters, minks, ferrets, raccoons, cats and dogs (Abdel-Moneim and Abdelwhab, 2020). Infections of lions, tigers, pumas, snow leopards, cynomolgus macaques, rhesus macaques, treeshrew, gorilla and others were also frequently reported (OIE, 2021). Clinical signs in animals are usually mild, but infections can also be fatal (de Morais et al., 2020; Ferasin et al., 2021). Several SARS-CoV-2 variants of concern (VOCs) are circulating worldwide and may even be more transmissible to and pathogenic for domestic animals than the original strain (Ferasin et al., 2021). There is also a possibility that such infected animals can more easily spill the virus back to humans. To date, rapid antigen tests (RATs) receive much attention as they provide on-site results without the need for elaborate instrumentation and/or expertise (Igloi et al., 2020). RATs are therefore part of most national testing strategies for humans worldwide. Hence, the question arose whether such assays would also be suitable as point-of-care diagnostics for SARS-CoV-2 in animals and, if so, whether the currently circulating VOCs are detected by them just as well. A broad analytical sensitivity study of 122 RATs for use in humans has shown recently that the majority of the assays are detecting SARS-CoV-2 viruses equivalent to about  $10^5$  genome copies (Scheiblauer et al., 2021). Another study on 5 commercial assays proved their suitability for detecting VOCs (B.1.1.7 and B.1.351) in principle but also revealed differences in analytical sensitivities for the variants (Jungnick et al., 2021). In the aforementioned test, VOCs were better detected than the original SARS-CoV-2 strains. VOCs are primarily defined by differences in spike protein, even though mutations in other viral proteins also exist. Therefore, it is not surprising that variable recognition by RATs, most of which use the nucleoprotein as a target, is observed between VOCs and common SARS-

1 CoV-2 strains. In the described study here, we used saliva samples spiked with cell culture  
2 grown virus to show that RATs are also suitable tool for detecting animals shedding SARS-  
3  
4 CoV-2. However, as it turned out limits of detection for VOC can also be substantially lower,  
5  
6 calling for detailed assay validations prior to their use.  
7  
8  
9

## 10 **Methods**

### 11 **Viruses and cells**

12  
13  
14 Vero E6 cells (ATCC CCL-81) were grown and maintained in Eagle's minimal essential  
15  
16 medium (EMEM; Lonza) with 8% foetal bovine serum (PAA), and antibiotics (Sigma) at 37°C  
17  
18 and 5% CO<sub>2</sub> as previously described (de Wilde et al., 2013). Infection of Vero E6 cells with  
19  
20 SARS-CoV-2 (strain 2019\_nCoV Muc-IMB-1, GISAID accession number EPI\_ISL\_406862)  
21  
22 and VOCs was performed as previously described (Case et al., 2020). Virus stocks (passage 3)  
23  
24 were stored at -80°C and viral titres depicted as TCID<sub>50</sub>/ml were calculated before use. All  
25  
26 work with live SARS-CoV-2 and VOCs was performed in a biosafety-level 3 (BSL-3)  
27  
28 laboratory at Friedrich-Loeffler-Institut, Germany. To perform downstream analysis under  
29  
30 BSL-2 conditions, viruses were heat-inactivated at 95°C for 20 minutes.  
31  
32  
33  
34  
35  
36  
37  
38  
39

### 40 **SARS-CoV-2 rapid antigen assays**

41  
42  
43 Rapid antigen assays were randomly selected from commercially available products. All assays  
44  
45 are registered for testing human naso/oropharyngeal swab samples and to detect SARS-CoV-2  
46  
47 N-protein using dual anti-N-antibodies; a dye-labeled antibody in the sample pad and  
48  
49 immobilized antibody fixed on a membrane. Upon adding a positive sample to the pad, the N-  
50  
51 protein is bound by the labeled antibody and the complex migrates by capillary forces and is  
52  
53 finally captured by the immobilized antibody. The test band gets visible by an accumulation of  
54  
55 the dye and the control band gets visible by capturing a labeled unspecific antibody. Here, we  
56  
57 aimed to evaluate limits of detection of SARS-CoV-2 rapid antigen assays by using serially  
58  
59  
60  
61  
62  
63  
64  
65

1 diluted heat-inactivated wild-type SARS-CoV-2 (Non-VOC; Wuhan-Hu-1 strain; TCID<sub>50</sub>  
2 10<sup>3.8</sup>/mL) and VOCs B.1.1.7 (TCID<sub>50</sub> 10<sup>6.75</sup>/mL) and B.1.351 (TCID<sub>50</sub> 10<sup>6.8</sup>/mL) in cell culture  
3  
4 medium composed of carbonate buffered MEM with Hanks and Earls salts (50:50), pyruvate,  
5  
6 non-essential amino acids and without antibiotics. Briefly, 25 µL from each viral dilution were  
7  
8 applied to the manufacturer swab and processed as recommended and finally eluted in 300 µL  
9  
10 from the supplied lysis buffer. After 120 µL from each swab suspension were applied to the  
11  
12 lateral flow device and 140 µL were subjected to RNA isolation and subsequent RT-qPCR  
13  
14 (Figure S1 A-B). We used these constant volumes in all assays for the comparability of  
15  
16 experiments. Results were recorded after 15 minutes and a 4-grade scaling readout (++++/strong  
17  
18 positive; ++/positive; +/weak positive; -/negative) was established to reflect the intensity of the  
19  
20 target band, which was furtherly quantified using Image Lab (Image Lab, 6.0.1; BioRad). When  
21  
22 results were dubious, the four or six-eye principle was used. Three independent and blinded  
23  
24 experiments were performed. To analyze the sensitivity and specificity of an exemplary rapid  
25  
26 antigen assay (BioNote), an additional double-fold dilution was performed to the borderline  
27  
28 dilution (e.g.10<sup>-3</sup>) to precisely reflect the borderline sensitivity and corresponding Ct values  
29  
30 (Figure S1 C-D). Data were further analyzed by receiver operating analysis (ROC) using  
31  
32 Sigmaplot (Systat Software Inc., Chicago, USA).  
33  
34  
35  
36  
37  
38  
39  
40  
41

### 42 **Detection of SARS-CoV-2 RNA by real-time RT-PCR**

43  
44  
45 Viral RNA from each swab suspension was extracted using QIAamp Viral RNA Mini Kit  
46  
47 (Qiagen, Hilden, Germany) and subjected to real-time RT-PCR (SuperScript III Reverse  
48  
49 Transcriptase, Invitrogen, Germany). An *envelope* (E) gene amplification was performed using  
50  
51 CFX real-time PCR systems (Bio-Rad, Germany) and a set of primers and probes as previously  
52  
53 described (Corman et al., 2020). Viral genome copy numbers were derived from the standard  
54  
55 curves of an *in vitro* RNA transcript harboring the E gene.  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## Spiking saliva with SARS-CoV-2

To evaluate the use of animal saliva in rapid antigen assays, we collected saliva from different species and spiked it with defined amounts of virus diluted in a cell culture medium. While human saliva was self-collected, ferrets and bats saliva were obtained by swabbing animals' oral fluid using manufacturer's swabs. The saliva-soaked swabs obtained from ferrets were directly spiked with the diluted virus, whereas bat' saliva was eluted from the swabs in PBS and solution was spiked with the virus as described. Saliva from cat and farm animals as sheep, goats, and cattle were obtained by passive drool collection. For collecting substances of swine saliva, a chewing-rope was used as previously described (M Gutierrez et al., 2014) and the wet part of the rope was eluted before applying it in antigen assay and RT-qPCR. Of note, collected saliva was processed by centrifugation at 14,000 rpm/30 min and filtration by 0.2  $\mu$ m filters to remove any debris. However, unprocessed saliva samples were also tested to exclude the inhibitory effect of saliva components such as mucin on RATs performance. Next, SARS-CoV-2 and VOCs were spiked, serially diluted into saliva, and 25  $\mu$ L were applied on the manufacturer's swab. Further, swabs were eluted in 300  $\mu$ L buffer and 120  $\mu$ L were applied on lateral devices. The percent of the target band intensity and corresponding viral gene copy numbers were reexamined as above described (Corman et al., 2020; Kennedy and Oswald, 2011). Importantly, an oropharyngeal swab from SARS-CoV-2-infected hamster was also used as an additional positive control, representing real-world clinical samples.

## Statistical analysis

GraphPad Prism (version 9; GraphPad Software, Inc., CA, USA) was used to analyse data. Normal distribution of data and analysis by Bonferroni's multiple comparisons tests was performed. Statistical analysis was performed using SPSS software (IBM Corp. Released 2011).

1 IBM SPSS Statistics for Windows, Version 20.0, IBM Corporation, Armonk, NY, USA).

2 Significance was considered upon P values  $\leq 0.05$ .

### 3 4 5 **Ethics statement**

6  
7  
8  
9 Collected human saliva was collected after required consent and without using any person-  
10 related data.  
11

### 12 13 14 **Results**

#### 15 16 17 **Effective detection of high and moderate wild-type SARS-CoV-2 loads by rapid antigen** 18 19 **assays** 20 21

22  
23  
24 Six assays showed detection limits down to  $10^3 - 10^4$  viral RNA genome copies pro mL (Figure  
25 1A), while for one assay virus dilutions equivalent to at least  $10^5$  viral copies and another  $10^6$   
26 genome copies were needed to obtain positive results (Figure 1A). Therefore, the least sensitive  
27 RAT was excluded from the study (Figure 1A). Based on these results, all rapid antigen assays  
28 were ranked according to their sensitivity and detection limits as shown in Table 1. To  
29 determine the cut-off value and the overall sensitivity of RATs, one exemplary assay (BioNote)  
30 was evaluated. For this experiment, virus dilutions corresponding to high, low and near-to-  
31 detection-limit viral loads were used. All samples rated positive by RAT were also positive by  
32 RT-qPCR (16/16) and only four samples were considered as false negative (4/18) (Figure 1B).  
33 Therefore, a cut-off value of Ct 32,25 was determined as a limit of detection (LoD) of rapid  
34 antigen assay (Figure 1B). This achieved an overall sensitivity of 93,75% with a ROC curve  
35 area of 98,61% when compared to RT-qPCR (Figure 1C).  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53

#### 54 55 **Saliva from animal species has no adverse effect on the sensitivity of rapid immunoassays**

56  
57  
58 To test whether saliva could have an impact on the analytical sensitivity of rapid antigen assays,  
59 we collected plain saliva from human and animal species and spiked them with SARS-CoV-2.  
60  
61  
62  
63  
64  
65

1 Saliva was collected either by swabbing oral fluids (as in bats and ferrets), passive drool  
2 collection (as in human, cat, sheep, goats, and cattle), or by chewing-ropes in swine as  
3  
4 previously described (M Gutierrez et al., 2014). SARS-CoV-2 non-VOC and VOC were serially  
5  
6 diluted into saliva and applied on lateral devices. Interestingly, both target and control bands  
7  
8 were detected on lateral devices using spiked animal saliva with no significant differences when  
9  
10 compared to previous results without using saliva (control) (Figures 2A). This clearly  
11  
12 demonstrates that saliva has no adverse effects on the sensitivity of antigen assays. Further, we  
13  
14 examined the corresponding viral genome copies by real-time RT-PCR and found no significant  
15  
16 impact on viral copy numbers upon using saliva as the detection limits were also about  $10^3$  –  
17  
18  $10^4$  viral copies (Figure 2B). Together, these results underline that saliva from the animal  
19  
20 species studied did not adversely affect the sensitivity of rapid antigen assays and/or real-time  
21  
22 RT-PCR.  
23  
24  
25  
26  
27  
28  
29

### 30 **Lower performance of rapid antigen tests for SARS-CoV-2 variants of concern B.1.1.7** 31 **and B.1.351** 32 33 34 35

36 To examine the potential effect of SARS-CoV-2 variants of concern on the sensitivity of antigen  
37  
38 assays, VOCs B.1.1.7 and B.1.351 were also included in this study. Surprisingly, the tested  
39  
40 antigen assays showed a significant reduction by nearly 1 log in LoD when VOCs were used  
41  
42 (Figure 3A-D). Further, we compared the corresponding SARS-CoV-2 Ct-values and gene copy  
43  
44 numbers and found a significant reduction by 1-2 logs ( $p < 0.0001$ , Figure 3E;  $p < 0.001$ , Figure  
45  
46 3F). Next, we aligned N-protein from wild-type SARS-CoV-2 and B.1.1.7 and B.1.351 variants  
47  
48 and found multiple amino acids substitutions in N-protein (Figure 3G). Whether these  
49  
50 substitutions significantly hampered efficient immune-detection of such variants by RATs  
51  
52 remained to be determined and worth future studies.  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## Discussion

1  
2  
3 Here most antigen assays were able to find positive results up to the level of Ct-value 32,25 and  
4  
5  $10^3$ - $10^4$  viral RNA genome copies respectively. However, there were also two assays with lower  
6  
7 sensitivities, rendering them less suitable for field applications (Figure 1A-B and Table 1). Our  
8  
9 data demonstrate that detection limits of rapid tests were up to 2 logs under the hypothetical  
10  
11 infectivity threshold (Wölfel et al., 2020), underlining their safety margin for detecting SARS-  
12  
13 CoV-2 infectious individuals and/or animals (Figure 1A). Initial reports on SARS-CoV-2  
14  
15 natural infections in animals as cats, dogs, and lions showed relatively high Ct values  $>30/35$   
16  
17 for positive animals showing clinical signs, suggesting missed infections upon using RATs  
18  
19 (Abdel-Moneim and Abdelwhab, 2020; de Morais et al., 2020; Segalés et al., 2020).  
20  
21 Nonetheless, as the virus continues to evolve and adapt in hosts, natural infections with lower  
22  
23 Ct values  $<25$  were recently reported, for instance in lions, where a RAT was successfully used  
24  
25 to detect the infection (Fernández-Bellon et al., 2021).  
26  
27  
28  
29  
30  
31

32  
33 Hundreds of rapid tests from different vendors are now available on the market (FIND, 2020)  
34  
35 and it is not surprising that some assays perform better than others. This, however, strongly  
36  
37 underlines the need for a regular and rigorous evaluation of rapid antigen tests before their  
38  
39 market approval. A leading-edge assay should be able to detect minimum SARS-CoV-2 and  
40  
41 VOC loads equivalent to  $10^3$ - $10^4$  viral RNA copies (per mL). Overall, rapid antigen tests  
42  
43 showed an analytical sensitivity of 93,75% when compared to RT-qPCR (Figure 1C).  
44  
45  
46  
47  
48

49 SARS-CoV-2 rapid tests rely on antigen-antibody reactions that can be inhibited by different  
50  
51 physiochemical properties of samples, e.g. viscosity and extreme pH values (Reverberi and  
52  
53 Reverberi, 2007). It is well known that animal saliva possesses a variable viscosity and pH  
54  
55 range (Reid and Huffman, 1949). Accordingly, whether animal saliva might affect the  
56  
57 sensitivity of SARS-CoV-2 antigen assays was an intriguing question that has been answered  
58  
59  
60  
61  
62

1 in this study. Neither saliva composition nor collection methods showed adverse effects on the  
2 sensitivity of rapid tests as interpreted qualitatively by lateral flows and quantitatively by  
3 relative band intensity (Figure 2A), and RT-qPCR (Figure 2B). Hence, antigen-antibody  
4 reactions can tolerate pH changes between 6.5-8.5 (Barnes, 1966; Hughes-Jones et al., 1964).  
5 Our data align with previous reports that recommended the use of saliva for detecting SARS-  
6 CoV-2 by antigen tests or RT-qPCR in humans (Basso et al., 2021; Wyllie et al., 2020).  
7

8  
9  
10  
11  
12  
13  
14  
15 B.1.1.7 and B.1.351 variants harbor mutations mainly in the S-gene that significantly impact S-  
16 gene targeting by RT-qPCR, a phenomenon known as S-gene dropout (Washington et al.,  
17 2020). Therefore, it is of utmost importance to detect whether mutations in other genes (e.g. N-  
18 gene) have an impact on the performance of these tests, especially commercial antigen assays  
19 that target N-protein (Figure 3G) (Azad, 2021). We observed that analytical sensitivities of  
20 RATs were significantly reduced especially at lower viral concentrations (Figure 3), which  
21 suggests a partial interaction between N-protein variants and lateral flow antibodies. The reason  
22 for that could be attributed to altered stability or epitopes of N-protein of B.1.1.7 and B.1.351  
23 variants.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

## 38 **Conclusion**

39  
40  
41  
42 In summary, saliva of the species tested has no impact on the functionality and performance of  
43 SARS-CoV-2 RATs. Therefore, the use of RATs can be recommended as a point-of-care  
44 surveillance tool for SARS-CoV-2 infections in these species. However, the tests should be  
45 checked beforehand for their suitability to equally detect VOC B.1.1.7 and B.1.351.  
46  
47  
48  
49  
50  
51

## 52 **Acknowledgments**

53  
54  
55  
56 We thank Katrin Schwabe for her technical assistance. Special thanks to Bärbel  
57 Hammerschmidt. Thanks are also extended to Virginia Friedrichs and Marcel Bokelmann.  
58  
59  
60  
61  
62  
63  
64  
65

## **Funding**

This work was made possible by intramural funding and was partially supported by funding from the COVRIN project of European Union's Horizon 2020 Research and Innovation programme under grant agreement No 773830: One Health European Joint Programme.

## **Author contributions**

ITH, MHG, MK conceived and designed the experiments. ITH, SW, MK performed experiments. ITH, SW, MHG, MK analyzed data. ITH, SW, MK contributed reagents/materials/analysis tools. ITH, MK, MHG attained funding. ITH, MHG, MK wrote the paper. All authors reviewed, edited, and approved the final version.

## **Conflict of interest**

No conflict of interest is declared

## **References**

- Abdel-Moneim, A.S., Abdelwhab, E.M., 2020. Evidence for SARS-CoV-2 infection of animal hosts. *Pathogens* 9, 529.
- Azad, G.K., 2021. Identification and molecular characterization of mutations in nucleocapsid phosphoprotein of SARS-CoV-2. *PeerJ* 9, e10666.
- Barnes, A.E., 1966. The specificity of pH and ionic strength effects on the kinetics of the Rh (D)-anti-Rh (D) system. *The Journal of Immunology* 96, 854-864.
- Basso, D., Aita, A., Padoan, A., Cosma, C., Navaglia, F., Moz, S., Contran, N., Zambon, C.-F., Cattelan, A.M., Plebani, M., 2021. Salivary SARS-CoV-2 antigen rapid detection: a prospective cohort study. *Clinica Chimica Acta* 517, 54-59.
- Case, J.B., Bailey, A.L., Kim, A.S., Chen, R.E., Diamond, M.S., 2020. Growth, detection, quantification, and inactivation of SARS-CoV-2. *Virology* 548, 39-48.

1 Corman, V.M., Landt, O., Kaiser, M., Molenkamp, R., Meijer, A., Chu, D.K., Bleicker, T.,  
2 Brünink, S., Schneider, J., Schmidt, M.L., 2020. Detection of 2019 novel coronavirus  
3 (2019-nCoV) by real-time RT-PCR. *Eurosurveillance* 25, 2000045.  
4  
5  
6  
7 de Morais, H.A., Dos Santos, A.P., do Nascimento, N.C., Kmetiuk, L.B., Barbosa, D.S.,  
8  
9 Brandão, P.E., Guimarães, A.M.S., Pettan-Brewer, C., Biondo, A.W., 2020. Natural  
10 infection by SARS-CoV-2 in companion animals: a review of case reports and current  
11 evidence of their role in the epidemiology of COVID-19. *Frontiers in veterinary*  
12 *science* 7, 823.  
13  
14  
15  
16  
17  
18  
19 de Wilde, A.H., Raj, V.S., Oudshoorn, D., Bestebroer, T.M., van Nieuwkoop, S., Limpens,  
20  
21 R.W., Posthuma, C.C., van der Meer, Y., Bárcena, M., Haagmans, B.L., 2013. MERS-  
22 coronavirus replication induces severe in vitro cytopathology and is strongly inhibited  
23 by cyclosporin A or interferon- $\alpha$  treatment. *The Journal of general virology* 94, 1749.  
24  
25  
26  
27  
28  
29 Ferasin, L., Fritz, M., Ferasin, H., Becquart, P., Legros, V., Leroy, E.M., 2021. Myocarditis in  
30 naturally infected pets with the British variant of COVID-19. *bioRxiv*.  
31  
32  
33  
34 Fernández-Bellon, H., Rodon, J., Fernández-Bastit, L., Almagro, V., Padilla-Solé, P., Lorca-  
35 Oró, C., Valle, R., Roca, N., Grazioli, S., Trogu, T., Bensaid, A., Carrillo, J.,  
36 Izquierdo-Useros, N., Blanco, J., Parera, M., Noguera-Julián, M., Clotet, B., Moreno,  
37 A., Segalés, J., Vergara-Alert, J., 2021. Monitoring Natural SARS-CoV-2 Infection in  
38 Lions (*Panthera leo*) at the Barcelona Zoo: Viral Dynamics and Host Responses.  
39 *Viruses* 13, 1683.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49 FIND, 2020. SARS- CoV- 2 Diagnostic Pipeline. FIND.  
50  
51 Hughes-Jones, N., Gardner, B., Telford, R., 1964. The effect of pH and ionic strength on the  
52 reaction between anti-D and erythrocytes. *Immunology* 7, 72.  
53  
54  
55  
56 Igloi, Z., Velzing, J., van Beek, J., van de Vijver, D., Aron, G., Ensing, R., Benschop, K.,  
57  
58 Han, W., Boelsums, T., Koopmans, M., 2020. Clinical evaluation of the Roche/SD  
59  
60  
61  
62  
63  
64  
65

1 Biosensor rapid antigen test with symptomatic, non-hospitalized patients in a  
2 municipal health service drive-through testing site. medRxiv.  
3

4 Jungnick, S., Hobmaier, B., Mautner, L., Hoyos, M., Haase, M., Baiker, A., Lahne, H.,  
5 Eberle, U., Wimmer, C., Hepner, S., 2021. Detection of the new SARS-CoV-2  
6 variants of concern B. 1.1. 7 and B. 1.351 in five SARS-CoV-2 rapid antigen tests  
7 (RATs), Germany, March 2021. Eurosurveillance 26, 2100413.  
8  
9

10 Kennedy, S., Oswald, N., 2011. PCR troubleshooting and optimization. Caister Academic  
11 Press.  
12  
13

14 M Gutierrez, A., J Ceron, J., Fuentes-Rubio, M., Tecles, F., A Beeley, J., 2014. A proteomic  
15 approach to porcine saliva. Current Protein and Peptide Science 15, 56-63.  
16  
17

18 OIE: OIE technical fact sheet - INFECTION WITH SARS-COV-2 IN ANIMALS. Available  
19 online:  
20  
21

22 [https://www.oie.int/fileadmin/Home/eng/Our\\_scientific\\_expertise/docs/pdf/COV-](https://www.oie.int/fileadmin/Home/eng/Our_scientific_expertise/docs/pdf/COV-19/A_Factsheet_SARS-CoV-2.pdf)  
23 [19/A\\_Factsheet\\_SARS-CoV-2.pdf](https://www.oie.int/fileadmin/Home/eng/Our_scientific_expertise/docs/pdf/COV-19/A_Factsheet_SARS-CoV-2.pdf) (accessed on 25.05.2021).  
24  
25

26 Reid, J., Huffman, C., 1949. Some physical and chemical properties of bovine saliva which  
27 may affect rumen digestion and synthesis. Journal of Dairy Science 32, 123-132.  
28  
29

30 Reverberi, R., Reverberi, L., 2007. Factors affecting the antigen-antibody reaction. Blood  
31 transfusion 5, 227.  
32  
33

34 Scheiblauber, H., Filomena, A., Nitsche, A., Puyskens, A., Corman, V.M., Drosten, C.,  
35 Zwirgmaier, K., Lange, C., Emmerich, P., Müller, M., Knauer, O., Nübling, C.M.,  
36 2021. Comparative sensitivity evaluation for 122 CE-marked SARS-CoV-2 antigen  
37 rapid tests. medRxiv, 2021.2005.2011.21257016.  
38  
39

40 Segalés, J., Puig, M., Rodon, J., Avila-Nieto, C., Carrillo, J., Cantero, G., Terrón, M.T., Cruz,  
41 S., Parera, M., Noguera-Julián, M., 2020. Detection of SARS-CoV-2 in a cat owned  
42 by a COVID-19- affected patient in Spain. Proceedings of the National Academy of  
43 Sciences 117, 24790-24793.  
44  
45  
46  
47  
48  
49  
50  
51  
52

1 Su, S., Wong, G., Shi, W., Liu, J., Lai, A.C., Zhou, J., Liu, W., Bi, Y., Gao, G.F., 2016.

2       Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends in  
3  
4       microbiology 24, 490-502.  
5  
6

7 Washington, N.L., White, S., Barrett, K.M.S., Cirulli, E.T., Bolze, A., Lu, J.T., 2020. S gene  
8  
9       dropout patterns in SARS-CoV-2 tests suggest spread of the H69del/V70del mutation  
10  
11       in the US. medRxiv.  
12  
13

14 Wölfel, R., Corman, V.M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M.A.,  
15  
16       Niemeyer, D., Jones, T.C., Vollmar, P., Rothe, C., 2020. Virological assessment of  
17  
18       hospitalized patients with COVID-2019. Nature 581, 465-469.  
19  
20

21 Wyllie, A.L., Fournier, J., Casanovas-Massana, A., Campbell, M., Tokuyama, M.,  
22  
23       Vijayakumar, P., Geng, B., Muenker, M.C., Moore, A.J., Vogels, C.B., 2020. Saliva is  
24  
25       more sensitive for SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal  
26  
27       swabs. MedRxiv.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## Figure captions

**Figure 1: Limits of detection (LoD) of SARS-CoV-2 rapid antigen assays.** (A) Comparison of the rapid antigen test results with the corresponding viral RNA genome copy numbers (per mL) determined by RT-qPCR. \* Antigen kits (WuHan UNscience) did not meet the requirements (weak positive at  $3.12 \times 10^6$  per mL), as the LoD was significantly different from the other tests (\* $p < 0.05$ ; Bonferroni's multiple comparisons). The dashed line refers to the hypothetical infectivity threshold ( $10^6$ /mL) (12). (B) Interactive dot analysis for an exemplary antigen assay (BioNote) results compared to RT-qPCR Ct values. The solid and dashed lines refer to the estimated Ct cut-off value 32.25 and the arbitrary limit of RT-qPCR Ct LoD, respectively. (C) ROC curve for the analysis of sensitivity and specificity of the leading rapid antigen tests (AUC 98.6;  $P < 0.001$ ). No significance was observed between assays (i-vii) ( $p$ -value  $\leq 0.05$ ). Three to four experiments were evaluated. One-way analysis of variance (ANOVA) with Bonferroni's multiple comparison test was used to analyse the data. Standard deviations ( $SD \pm$ ) are represented by error bars.


**Figure 2: Saliva from animal species has no adverse effect on the analytical sensitivity of rapid antigen assays.** (A) SARS-CoV-2 target band intensity (%) in lateral flow device after normalization to the control band. (B) SARS-CoV-2 copy numbers from spiked human and animal species saliva with correspondence to the results of lateral flow device using real-time RT-PCR. Controls blue and black respectively represent non-saliva sample and an oropharyngeal swab from SARS-CoV-2-infected hamster (Positive clinical sample). Non-applicable data (test band missing, therefore no calculation possible) were referred to as 'na'. Three to four average data sets were analysed. Standard deviations ( $SD \pm$ ) are represented by error bars. No significant differences were detected (Control vs. human, feline, ferrets, cattle, sheep, swine, and bats; Bonferroni's multiple comparisons test; Significance level was set at  $p$ -value  $\leq 0.05$ ).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65


**Figure 3: Partial impairment of analytical sensitivity of antigen assays by B.1.1.7 and B.1.351 VOC. (A), (B), and (C)** Qualitative results of an exemplary antigen assay (BioNote) using serially diluted cell culture supernatants from SARS-CoV-2 and VOC B.1.1.7 and B.1.351 (Fig. S2). **(D)** Quantitative comparison of band intensities (%) of SARS-CoV-2 and VOCs. **(E)** and **(F)** Comparison of borderline detection limit (+) of antigen assay (BioNote/NowCheck) in case of eluted SARS-CoV-2 and VOCs using Ct-values and gene copy numbers (\*\*\*\* $p < 0.0001$ ; \*\* $p < 0.01$ ; \* $p < 0.05$ ). **(G)** Alignment of N-protein sequences of SARS-CoV-2 and VOC, highlighting changes in amino acids residues. Three to four average data sets were analysed. Standard deviations ( $SD \pm$ ) are depicted by error bars. The one-way analysis of variance (ANOVA) with Bonferroni's multiple comparisons test was used to analyse data.

**Figure 1**

**A**



**B**



**C**




Figure 2





Figure 3

